Chronic intrauterine exposure to psychoactive drugs often results in neonatal opioid
withdrawal syndrome (NOWS). When nonpharmacologic measures are insufficient in …

Introduction Neonatal opioid withdrawal syndrome (NOWS) often arises in infants born to
mothers who used opioids during pregnancy. Morphine, methadone, and buprenorphine are …

Neonates born to mothers taking opioids during pregnancy are at risk for neonatal opioid
withdrawal syndrome (NOWS), for which there is no recognized standard approach to care …

In this paper, we review the management of neonatal opioid withdrawal syndrome (NOWS)
and clinical pharmacology of primary treatment agents in NOWS, including morphine …

Tens of thousands of infants are impacted yearly by prenatal opioid exposure. The term
neonatal opioid withdrawal syndrome (NOWS) is now replacing the more familiar term …

Background: Neonatal opioid withdrawal syndrome (NOWS) is a significant and growing
health problem that affects more than 23,000 infants annually, with an estimated hospital …

Objectives To compare clinical outcomes for infants with neonatal opioid withdrawal
syndrome (NOWS) treated with buprenorphine or morphine. Study design Retrospective …

Introduction Rates of neonatal opioid withdrawal syndrome (NOWS) have paralleled the rise
of opioid use during pregnancy. While short-term phenotypic symptoms of NOWS are well …

A significant number of advances have been made in the last 5 years with respect to the
identification, diagnosis, assessment, and management of infants with prenatal opioid …

Neonates who have had in utero exposures from maternal substance abuse can experience
central nervous system effects of the drugs, including drug toxicity and withdrawal. Neonatal …